drugset / Trial / NCT00036855
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy with or without peripheral stem cell transplantation in treating patients who have recurrent or refractory lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver radioactive tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by anticancer therapy
Timeline
- Start
- 2002-06
- Primary completion
- 2005-03
- Completion
- —
Outcome
Outcome not reported
Stopped: “Administratively complete.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |